Article Text

Download PDFPDF

Correspondence on ‘Immunogenicity and safety of anti-SARS-Cov-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort’
  1. Chiara Salviani1,
  2. Francesco Scolari1,2,
  3. Federico Alberici1,2
  1. 1 Nephrology Unit, ASST Spedali Civili di Brescia, Brescia, Italy
  2. 2 Department of Medical and Surgical Specialties, University of Brescia, Brescia, Italy
  1. Correspondence to Dr Chiara Salviani, Nephrology Unit, ASST Spedali Civili di Brescia, Piazzale Spedali Civili 1, 25125, Brescia, Lombardia, Italy; chiara.salviani{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We read with great interest the article by Geisen et al.1 The authors reported a considerable immunogenicity of mRNA vaccines against SARS-CoV-2 in patients with chronic inflammatory diseases receiving immunosuppression; noteworthy, none was on B-cell depleting agents.

Rituximab (RTX) is one of the mainstays of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) treatment, both for induction and maintenance therapy2; of note, recent data have shown that RTX therapy was associated with poorer COVID-19-related outcomes in patients with rheumatic diseases.3

In the absence of an effective treatment, vaccination would be a promising tool to prevent severe COVID-19 in immunocompromised patients.

Only four cases addressing the issue of antibody production after SARS-CoV-2 infection in patients with AAV treated with RTX are available in literature,4–6 while no data about antibody production after vaccination have been published yet.

We describe here the case of two AAV patients who did not produce neutralising antibodies after mRNA vaccination against SARS-CoV-2 (cases 1 and 2); we also report the case of a patient who experienced COVID-19 while B-cell depleted without seroconversion (case 3).

Case 1: a 31-year-old woman presenting with nasal crusting and saddle nose deformity, bilateral effusive otitis media, isolated microhaematuria and anti-myeloperoxidase (MPO) positive ANCA, was diagnosed with granulomatosis with polyangiitis (GPA) in February 2018. Induction therapy consisted of glucocorticoids and 4 weekly infusions of RTX (375 mg/m2), obtaining complete remission. Subsequently, maintenance therapy was started, with four scheduled infusions of RTX (500 mg each) every 6 months. Last infusion was administered on the 26 June 2020. In January 2021, while on maintenance therapy with prednisone 5 and 2.5 mg on alternate days, she received mRNA vaccine against SARS-CoV-2. At the time of vaccination, peripheral B cell count was 0 cells/mm3, immunoglobulin levels were normal. No anti-SARS-CoV-2 spike protein antibodies were detectable at the test performed 60 days later (March 2021).

Case 2: a 60-year-old woman was diagnosed with MPO-ANCA positive GPA in October 2014. She presented with constitutional symptoms (fever, weight loss, weakness), bilateral dacryoadenitis and episcleritis, microhaematuria and low-grade proteinuria. She received glucocorticoids and two infusions of RTX (1 g each) 2 weeks apart for remission induction. Maintenance therapy with methotrexate was then started. From November 2018, she was retreated with RTX (four scheduled infusions of 500 mg every 6 months) due to B-cell repopulation and ANCA positivity; methotrexate was withdrawn. Last RTX infusion was administered on 24 June 2020. In January 2021, she received mRNA vaccine against SARS-CoV-2. At that time, B-cell count was 0 cells/mm3 and immunoglobulin levels normal. Maintenance therapy consisted of prednisone 5 mg/day. Sixty days later (March 2021), no anti-SARS-CoV-2 spike protein antibodies were detectable.

Case 3: a 43-year-old woman was diagnosed with biopsy proven ANCA-negative localised GPA in September 2019. She had nasal crusting and subglottic stenosis. She received glucocorticoids and four infusions of RTX (375 mg/m2 each) for remission induction. Due to COVID-19 pandemic, a maintenance RTX infusion (500 mg) was delayed to the 26 June 2020. In September 2020, peripheral B-cell count was 0 cells/mm3 and immunoglobulin levels normal. From the 31 October 2020, she developed fever, cough, headache and weakness. On the 4 November 2020, a nasopharyngeal swab for SARS-CoV-2 tested positive. She was treated with glucocorticoids, enoxaparin and azithromycin with complete recovery and no need for hospitalisation. In March 2021, she underwent a serological test for anti-SARS-CoV-2 spike protein antibodies and none was detected.

In patients treated with RTX, a blunted response to several vaccinations, including those against seasonal influenza, Pneumococcus and tetanus,7 8 has already been reported.

Of note, the two patients here described did not develop neutralising antibodies after mRNA vaccine against SARS-CoV-2, even though last infusion of RTX dated back to 9 months earlier.

Data on seroconversion after SARS-CoV-2 infection in AAV patients treated with RTX are scanty but available. To date, only four cases have been published: three patients were B-cell depleted and one B-cell reconstituted (10 cells/mm3) at the time of the infection. Of note, the latter developed IgG towards SARS-CoV-2 while, among the former three, only one showed low titre of neutralising antibodies (table 1).

Table 1

Antibody response to SARS-CoV-2 infection in AAV patients

Guidelines for RTX treated patients recommend to perform vaccination at least 4 weeks prior or 6 months after infusion.9 However, in AAV patients, a more delayed B-cell repopulation has been described compared with other immunological diseases.10 Of note, up to more than 60 months of B-cell depletion after induction with RTX has been described in AAV patients, suggesting an intrinsic dysregulation of the B-cell compartment in this disease.11 Therefore, in addition to the timing since last RTX infusion, we believe that in this group of patients also B-cell count should be taken into account when planning vaccination.

Although results from single case reports cannot be generalised, our data raise concerns about the risk of an inadequate seroconversion after SARS-CoV-2 vaccine in AAV patients treated with RTX.

Ethics statements

Ethics approval

Ethical approval for this study was obtained according to Italian regulations.



  • Contributors CS planned the study, collected the data, drafted the manuscript. FS planned the study, reviewed the manuscript. FA planned the study, recruited the patients, reviewed the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Provenance and peer review Not commissioned; internally peer reviewed.